By Billy Candra 
This groundbreaking research, conducted by a team led by Dr. Peter Dirks, Senior Scientist in the Developmental, Stem Cell & Cancer Biology program and Chief of the Division of Neurosurgery at SickKids, focuses on sonic hedgehog (SHH) medulloblastoma. The findings, published in Nature Communications, identify a critical protein responsible for awakening dormant stem cells, thereby driving both the formation and regrowth of these aggressive tumours. By successfully blocking this protein, the study offers a potentially transformative treatment strategy that leverages sophisticated genomic approaches in conjunction with functional experiments in preclinical models.
Medulloblastoma: A Formidable Foe in Childhood Cancer
Medulloblastoma stands as the most common malignant brain tumour in children, accounting for approximately 20% of all pediatric brain cancers. Affecting roughly 250 children and adolescents in North America each year, its incidence peaks between the ages of 3 and 8. While survival rates have improved over the past few decades, reaching around 70-80% for standard-risk cases, a significant proportion of children still face daunting prognoses, particularly those with high-risk or recurrent disease. Moreover, survivors often endure severe, lifelong side effects from intensive treatments, including cognitive impairments, endocrine dysfunction, hearing loss, and secondary cancers, significantly impacting their quality of life.
The SHH subtype, one of four molecular subgroups of medulloblastoma, accounts for about 30% of cases and is characterized by overactivation of the sonic hedgehog signaling pathway, crucial for normal brain development. However, in cancer, this pathway becomes aberrantly active, fueling uncontrolled cell proliferation. This subtype can occur across all pediatric age groups, though it is more common in infants and adults. The unique molecular profile of SHH medulloblastoma makes it a prime target for precision medicine approaches.
The Intractable Challenge of Brain Tumour Research
Brain cancer presents a unique constellation of challenges for researchers and clinicians alike. The brain’s delicate and complex environment, protected by the blood-brain barrier (BBB), severely limits the delivery of therapeutic agents. Furthermore, by the time symptoms manifest—often subtle and non-specific, such as headaches, nausea, or changes in balance—tumours are frequently advanced, highly heterogeneous, and have developed intricate resistance mechanisms. This complexity often obscures the fundamental drivers of tumour growth, making targeted treatment difficult.
Traditional treatments for medulloblastoma typically involve a multi-modal approach: surgical resection, followed by radiation therapy (especially craniospinal irradiation) and intensive chemotherapy. While effective in many cases, these therapies are non-specific, damaging healthy brain tissue alongside cancerous cells, leading to the aforementioned debilitating long-term sequelae. The concept of cancer stem cells (CSCs) has emerged as a critical factor in tumour recurrence and resistance. These rare cells within a tumour possess self-renewal capabilities and are highly resistant to conventional therapies, acting as the ‘seeds’ for new tumour growth after initial treatment. Addressing these resilient cells is paramount to preventing relapse.
Pioneering Cancer Interception: A Paradigm Shift
The research from SickKids introduces the compelling concept of "cancer interception." Unlike conventional therapies that react to an established tumour, interception aims to halt the cancerous process at its earliest stages, either preventing tumour formation entirely or stopping its recurrence before it becomes clinically apparent. This proactive strategy represents a significant paradigm shift in oncology, moving towards preventative or pre-emptive treatment rather than reactive intervention.
"Our findings offer a novel strategy to target cancer stem cells, providing hope for more effective treatments against aggressive brain tumors," remarked Dr. Dirks. This approach is particularly relevant for brain cancers, where early intervention can mitigate the devastating impact of tumour growth on neurological function and minimize the need for highly toxic, brain-damaging treatments.
Unraveling the Mechanism: The Role of OLIG2
The Dirks team initiated their investigation by meticulously examining the cellular transitions that underpin the development of SHH medulloblastoma tumours. Their detailed analysis revealed that a specific protein, OLIG2, plays a pivotal role in activating quiescent, or ‘sleeping,’ stem cells. These stem cells, once activated, begin to divide uncontrollably, leading to the formation of a tumour. Crucially, OLIG2 was also found to reactivate these stem cells after conventional treatments, driving tumour regrowth and relapse.
"There is order to how the cancer initiating stem cells undergo fate changes to form tumours. We can target an early transition event and intercept the entire process — essentially stopping the cancer in its earliest form," explained Dr. Kinjal Desai, the first author of the study and a postdoctoral researcher in the Dirks lab. This understanding of the precise molecular choreography involved in tumour initiation and recurrence allowed the researchers to identify a critical window for intervention. OLIG2, a transcription factor, is known to be involved in the development of oligodendrocytes, a type of glial cell in the central nervous system. Its aberrant activation in cancer stem cells highlights a hijacking of normal developmental pathways to fuel oncogenesis.
CT-179: A Targeted Molecular Intervention
Armed with the knowledge of OLIG2’s central role, the research team sought a therapeutic agent that could specifically disrupt its function. Their efforts led them to a small molecule called CT-179. This compound was found to effectively block the activity of the OLIG2 protein, thereby preventing the activation and subsequent proliferation of the ‘sleeping’ stem cells.
The study demonstrated the efficacy of CT-179 in two critical scenarios within preclinical models. Firstly, by combining CT-179 with a previously established conventional treatment, the researchers were able to target residual stem cells that typically survive initial therapy. By preventing these cells from re-awakening and re-initiating tumour growth, CT-179 effectively prevented tumour relapse. This has profound implications for improving long-term survival and reducing the burden of recurrent disease. Secondly, for early-stage SHH medulloblastoma, CT-179 administered proactively prevented the tumour from forming altogether and significantly increased survival rates in the preclinical models. This latter finding particularly underscores the potential for true cancer interception.
Collaborative Validation and Broader Therapeutic Horizon
The robustness of these findings is further bolstered by a simultaneous study published in Nature Communications by research teams from Children’s Healthcare of Atlanta and QIMR Berghofer Medical Research Institute in Australia. These independent studies, utilizing additional preclinical models, corroborated the critical role of OLIG2 and the therapeutic potential of its inhibition, providing strong validation for the SickKids’ discovery. This international collaboration underscores the global effort in tackling pediatric brain cancers and the shared urgency to find more effective and less toxic treatments.
Crucially, the implications of this research extend beyond SHH medulloblastoma. The findings showcase what could be an effective new treatment strategy for other aggressive brain cancers, including Diffuse Intrinsic Pontine Glioma (DIPG). DIPG is an exceedingly aggressive and uniformly fatal pediatric brain tumour, typically diagnosed in young children, with a median survival of less than a year. Its location in the brainstem makes surgical removal impossible, and it is highly resistant to radiation and chemotherapy. A similar mechanism involving stem cell activation could potentially be at play in DIPG, offering a beacon of hope for this devastating disease.
This study also complements recent research from the Dirks Lab published in Nature, which elucidated the early stages of glioblastoma development. This consistent line of inquiry demonstrates a focused and productive research program dedicated to understanding the fundamental mechanisms of brain tumour initiation and progression, ultimately aiming to translate these insights into clinical benefits.
Precision Biology: A Future of Prevention and Early Intervention
The diagnostic potential of this discovery is a source of immense excitement for the Dirks lab, which is an integral part of the Arthur and Sonia Labatt Brain Tumour Research Centre (BTRC). Dr. Dirks envisions a future where this "magic bullet" for early treatment could be seamlessly integrated with advanced diagnostic tests to potentially prevent cancer from developing at all.
"At SickKids, we’re already genetically testing every child with cancer to inform their diagnosis and treatments — our study goes beyond genetic testing to precision biology," Dr. Dirks stated. This signifies a move from simply identifying genetic mutations to understanding the precise biological pathways that drive cancer and intervening at the earliest possible juncture. For patients currently being monitored for relapse, the ability to identify and target these ‘sleeping’ stem cells before they re-awaken could revolutionize post-treatment surveillance and intervention strategies.
While future research will involve expanding these preclinical findings into rigorous clinical trials for patients, particularly among those at high risk of relapse or with early markers of the disease, the foundational science provides a strong impetus for this next phase. The development of biomarkers to identify patients who would benefit most from OLIG2 inhibition and the optimization of CT-179 for human use will be critical steps.
Broad Impact and Community Endorsement
The implications of this breakthrough resonate deeply within the pediatric oncology community, patient advocacy groups, and funding organizations. Experts in pediatric neuro-oncology emphasize the urgent need for therapies that are both more effective against aggressive brain tumours and less detrimental to a child’s developing brain. This research directly addresses both these imperatives.
Patient advocacy groups, such as Jessica’s Footprint Foundation, Hopeful Minds Foundation, b.r.a.i.n.child, and Meagan’s Walk, which are among the generous funders of this study, have consistently championed research aimed at improving outcomes and reducing the long-term burden for children with brain cancer. These organizations often provide vital support for families and recognize the profound impact that a preventative or relapse-inhibiting therapy could have on the lives of countless children and their families. A representative from a major funding body, while not specifically quoted, would likely underscore the strategic importance of investing in foundational research that tackles the root causes of cancer, especially in areas with high unmet medical needs like pediatric brain tumours.
Beyond the immediate clinical benefits, the development of an effective cancer interception strategy has broader societal and economic implications. Reducing the incidence of relapse and the severity of treatment-related side effects would lead to a substantial decrease in healthcare costs associated with long-term care, rehabilitation, and managing chronic conditions. More importantly, it would enable more children to lead full, healthy, and productive lives, unburdened by the enduring sequelae of brain cancer and its aggressive treatments.
This pivotal study was made possible through the generous support of numerous organizations dedicated to advancing cancer research, including the Canadian Institutes of Health Research (CIHR), Ontario Institute for Cancer Research, Terry Fox Research Institute, Canadian Cancer Society, Cancer Research UK, Stand Up to Cancer, Jessica’s Footprint Foundation, Hopeful Minds Foundation, b.r.a.i.n.child, Meagan’s Walk, Garron Family Cancer Centre, the Bresler family, and SickKids Foundation. Their collective commitment underscores the collaborative spirit and sustained investment required to translate scientific discovery into tangible hope for patients.
